Pancreatic Cancer | Topics

Michael Kim, MD, Discusses Study on Mutant p53 and Oncogenic KRAS in Pancreatic Cancer
April 10, 2021

The MD Anderson expert discussed the main takeaway from the data published during the virtual AACR Annual Meeting, while looking forward to what comes next with these genetic drivers.

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer
February 25, 2021

According to investigators, study findings could help guide treatment decisions and future research, as well as suggest new biomarkers for exploration.

Phase 3 Study Explores Pamrevlumab for Unresectable LAPC
February 17, 2021

The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.